Neos Therapeutics (NEOS) Misses Q2 EPS by 8c, Revenues Miss

Neos Therapeutics (NASDAQ: NEOS) reported Q2 EPS of ($0.52), $0.08 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $11.36 million versus the consensus estimate of $12.1 million.

“Second quarter revenues for our ADHD products were $10.8 million which represents a 22.5% growth over first quarter revenues. With over 7,500 prescribers of Adzenys XR-ODT and over 4,700 prescribers of Cotempla XR-ODT in the second quarter alone, we believe we are in a strong position to drive prescription growth as many school-aged ADHD patients visit their health care provider for back to school physicals,” said Jerry McLaughlin, Chief Executive Officer of Neos Therapeutics. “Our ADHD products provide a solid and growing base of business and our primary goals are to continue to increase market share for these products, achieve profitability and strategically expand our pipeline and commercial product portfolio. With continued careful management of our cash flow, we are happy to report a cash position of approximately $29.1 million at the end of July versus a cash position of $28.0 million at the end of June.”

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Visa (V) stock rises as Q2 earnings, revenue come ahead of estimates
• Equity Residential (EQR) Tops Q1 EPS by 44c; offers guidance
• Retail Opportunity Investments (ROIC) Tops Q1 EPS by 2c, reaffirms guidance